Incyte Strikes Deals with Bayer, Lilly; Hires Vuko | GenomeWeb

P

ALO ALTO, Calif.--Incyte Pharmaceuticals won another LifeSeq subscriber last week and expanded its licensing arrangement with an existing subscriber. In a new deal, Bayer subscribed to the LifeSeq Gold database for therapeutic protein discovery, gaining access to Incyte’s portfolio of more than 50,000 genes. Incyte did not reveal terms of the deal, and said only that it could receive future milestone payments and royalties on product sales.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.